Search Results

Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen’s differentiated PARP inhibitor RP12146, indicates a superior haematological safety profile that the company expects will translate through ongoing clinical trials.

Rhizen Pharmaceuticals AG, a Swiss based privately held, clinical-stage biopharmaceutical company announced that it is presenting data from an ongoing Phase 2 trial of Tenalisib in locally advanced or metastatic breast cancer and data from a concluded dose escalation phase of RP12146 at ESMO 2022, Paris from Sept 9-13, 2022.

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.

Rhizen Pharmaceuticals AG, a Switzerland-based privately held, clinical-stage biopharmaceutical company announced that it is presenting promising interim data from an ongoing Ph2 trial of Tenalisib in locally advanced or metastatic breast cancer patients, at the ESMO Breast Cancer Meeting, in Berlin, Germany from May 3-5, 2022.

Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.

Pharmaceutical companies are combining antibodies with radioisotopes in a bid to more precisely deliver radiation to cancers and tumors.

Rhizen Pharma commences dosing in a phase I/Ib trial to evaluate its novel PARP inhibitor (RP12146) in patients with advanced cancers.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa) today announced its sponsorship of the American Heart Association’s new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis.

Catalyst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE.